- Home
- HUIZ vs KPRX Comparison
HUIZ vs KPRX Comparison
Compare HUIZ & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HUIZ | KPRX |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 11.3M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HUIZ | KPRX |
|---|---|---|
| Price | $1.34 | $2.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 31.0K | 11.6K |
| Earning Date | 08-20-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.48 | N/A |
| Revenue Next Year | $6.59 | N/A |
| P/E Ratio | $7.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.04 | $1.76 |
| 52 Week High | $4.16 | $2.95 |
Technical Indicators
Market Signals| Indicator | HUIZ | KPRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 45.53 |
| Support Level | $1.17 | $2.45 |
| Resistance Level | $1.55 | $2.61 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 17.07 | 0.00 |
Price Performance
Historical ComparisonAbout HUIZ Huize Holding Limited
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners. Geographically, the company is concentrated in PRC Mainland, Hong Kong and others segments.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.